Literature DB >> 31733702

Orthostatic Hypotension in Parkinson Disease.

Jose-Alberto Palma1, Horacio Kaufmann2.   

Abstract

Orthostatic hypotension (OH) is a sustained fall in blood pressure on standing that can cause symptoms of organ hypoperfusion. OH is associated with increased morbidity and mortality and leads to a significant number of hospital admissions. OH can be caused by volume depletion, blood loss, cardiac pump failure, large varicose veins, medications, or defective activation of sympathetic nerves and reduced norepinephrine release upon standing. Neurogenic OH is a frequent and disabling problem in patients with synucleinopathies such as Parkinson disease, multiple system atrophy, and pure autonomic failure, and it is commonly associated with supine hypertension. Several therapeutic options are available.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autonomic failure; Baroreflex dysfunction; Droxidopa; Midodrine; Neurogenic orthostatic hypotension; Norepinephrine

Mesh:

Year:  2019        PMID: 31733702      PMCID: PMC7029426          DOI: 10.1016/j.cger.2019.09.002

Source DB:  PubMed          Journal:  Clin Geriatr Med        ISSN: 0749-0690            Impact factor:   3.076


  89 in total

1.  Synergistic effect of norepinephrine transporter blockade and α-2 antagonism on blood pressure in autonomic failure.

Authors:  Luis E Okamoto; Cyndya Shibao; Alfredo Gamboa; Leena Choi; André Diedrich; Satish R Raj; Bonnie K Black; David Robertson; Italo Biaggioni
Journal:  Hypertension       Date:  2012-02-06       Impact factor: 10.190

2.  Nocturnal hypertension and dysautonomia in patients with Parkinson's disease: are they related?

Authors:  Koldo Berganzo; Begoña Díez-Arrola; Beatriz Tijero; Johanne Somme; Elena Lezcano; Verónica Llorens; Iratxe Ugarriza; Roberto Ciordia; J C Gómez-Esteban; Juan J Zarranz
Journal:  J Neurol       Date:  2013-02-15       Impact factor: 4.849

3.  Autoregulatory cerebral vasodilation occurs during orthostatic hypotension in patients with primary autonomic failure.

Authors:  D R Horowitz; H Kaufmann
Journal:  Clin Auton Res       Date:  2001-12       Impact factor: 4.435

4.  Orthostatic hypotension and the incidence of coronary heart disease: the Atherosclerosis Risk in Communities study.

Authors:  K M Rose; H A Tyroler; C J Nardo; D K Arnett; K C Light; W Rosamond; A R Sharrett; M Szklo
Journal:  Am J Hypertens       Date:  2000-06       Impact factor: 2.689

5.  Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group.

Authors:  P A Low; J L Gilden; R Freeman; K N Sheng; M A McElligott
Journal:  JAMA       Date:  1997-04-02       Impact factor: 56.272

6.  Droxidopa in neurogenic orthostatic hypotension.

Authors:  Horacio Kaufmann; Lucy Norcliffe-Kaufmann; Jose-Alberto Palma
Journal:  Expert Rev Cardiovasc Ther       Date:  2015-06-19

7.  Physical manoeuvres that reduce postural hypotension in autonomic failure.

Authors:  W Wieling; J J van Lieshout; A M van Leeuwen
Journal:  Clin Auton Res       Date:  1993-02       Impact factor: 4.435

Review 8.  Midodrine. A review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders.

Authors:  D McTavish; K L Goa
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

9.  Neurogenic orthostatic hypotension: the very basics.

Authors:  Horacio Kaufmann; Jose-Alberto Palma
Journal:  Clin Auton Res       Date:  2017-06-15       Impact factor: 4.435

10.  Fludrocortisone Is Associated With a Higher Risk of All-Cause Hospitalizations Compared With Midodrine in Patients With Orthostatic Hypotension.

Authors:  Carlos G Grijalva; Italo Biaggioni; Marie R Griffin; Cyndya A Shibao
Journal:  J Am Heart Assoc       Date:  2017-10-12       Impact factor: 5.501

View more
  8 in total

1.  Assessment of Abdominal Constrictor's Forces for Informing Computational Models of Orthostatic Hypotension.

Authors:  Faiz Syed; Rejath Jose; Timothy Devine; Chris Coletti; Milan Toma
Journal:  Materials (Basel)       Date:  2022-04-26       Impact factor: 3.748

2.  Levodopa-Carbidopa Intestinal Gel Improves Symptoms of Orthostatic Hypotension in Patients with Parkinson's Disease-Prospective Pilot Interventional Study.

Authors:  Simona Stanková; Igor Straka; Zuzana Košutzká; Peter Valkovič; Michal Minár
Journal:  J Pers Med       Date:  2022-04-29

Review 3.  Skin alpha-synuclein deposit patterns: A predictor of Parkinson's disease subtypes.

Authors:  Yihang Han; Di Wu; Yanjuan Wang; Jian Xie; Zhijun Zhang
Journal:  EBioMedicine       Date:  2022-05-26       Impact factor: 11.205

Review 4.  Autonomic Dysfunction in Parkinson's Disease.

Authors:  Ronald F Pfeiffer
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

Review 5.  Altered cardiorespiratory regulation during exercise in patients with Parkinson's disease: A challenging non-motor feature.

Authors:  Jeann L Sabino-Carvalho; Lauro C Vianna
Journal:  SAGE Open Med       Date:  2020-05-06

Review 6.  Autonomic Function in Patients With Parkinson's Disease: From Rest to Exercise.

Authors:  Jeann L Sabino-Carvalho; James P Fisher; Lauro C Vianna
Journal:  Front Physiol       Date:  2021-03-19       Impact factor: 4.566

Review 7.  Sudden unexpected death in Parkinson's disease: Insights from clinical practice.

Authors:  Fulvio A Scorza; Marcia Guimarães-Marques; Mariana Nejm; Antônio Carlos G de Almeida; Carla A Scorza; Ana C Fiorini; Josef Finsterer
Journal:  Clinics (Sao Paulo)       Date:  2022-02-10       Impact factor: 2.365

Review 8.  Passive Immunization in Alpha-Synuclein Preclinical Animal Models.

Authors:  Jonas Folke; Nelson Ferreira; Tomasz Brudek; Per Borghammer; Nathalie Van Den Berge
Journal:  Biomolecules       Date:  2022-01-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.